scholarly journals Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function

2008 ◽  
Vol 101 (4) ◽  
pp. 492-497 ◽  
Author(s):  
L.M. Staals ◽  
M.M.J. Snoeck ◽  
J.J. Driessen ◽  
E.A. Flockton ◽  
M. Heeringa ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Normal Renal Function ◽  
Comparative Trial ◽  
Efficacy And Safety ◽  
End Stage Renal Failure ◽  
Parallel Group ◽  
End Stage

Functional Characteristics of Peritoneal Macrophages of Renal Failure Patients on Peritoneal Dialysis

1991 ◽  
Vol 11 (3) ◽  
pp. 265-269 ◽  
Author(s):  
Wladyslaw Sulowicz ◽  
Zygmunt Hanicki ◽  
Tadeusz Chichocki ◽  
Marek Zembala ◽  
Irena Ruggiero ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Peritoneal Dialysis ◽  
Normal Renal Function ◽  
Functional Activity ◽  
Functional Expression ◽  
Peritoneal Macrophages ◽  
End Stage Renal Failure ◽  
Bacterial Peritonitis ◽  
End Stage

Functional activity of peritoneal macrophages of 50 patients with end-stage renal failure on intermittent peritoneal dialysis (IPD) and of 30 control subjects with normal renal function was determined. Phagocytosis of latex particles by macrophages of dialyzed patients was significantly lower as compared with the controls. Further depression of the phagocytic activity was observed during bacterial peritonitis. Macrophages from the dialyzed patients also showed nonsignificantly decreased functional expression of Fc receptors (FcR) and increased spontaneous nitro blue tetrazolium (NeT) reduction.

Oral and Maxillofacial Manifestations of Mineral and Bone Disorders Associated with Chronic Renal Failure

2017 ◽  
Vol 68 (6) ◽  
pp. 1325-1328
Author(s):  
Andrada Raluca Doscas ◽  
Mihail Balan ◽  
Mihai Liviu Ciofu ◽  
Doriana Agop Forna ◽  
Marius Cristian Martu ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Failure ◽  
Renal Function ◽  
Chronic Renal Failure ◽  
Health Concern ◽  
Oral Manifestations ◽  
End Stage Renal Failure ◽  
Brown Tumors ◽  
The Mean ◽  
End Stage

Chronic kidney disease (CKD) is a multifactorial syndrome and a global health concern. As renal function declines, there is a progressive deterioration of mineral homeostasis. Starting from stage 3 of CKD oral manifestations of mineral disorders can occasionally appear and become more frequent and evident in stage 5. We retrospectively analysed 43 patients diagnosed with end stage renal failure undergoing dialysis, hospitalized in our clinic for different oral and maxillofacial pathologies. The mean dialysis period was 5.43 years. Radiographic alterations afecting the jaws were found in all patients. The most common feature was partial or total loss of lamina dura, followed by alterations of the bony trabeculae. 9 patients presented brown tumors which are considered the final stage of secondary hyperparathyroidism associated with renal failure.

scholarly journals Residual renal function with different frequencies of hemodialysis treatment in end-stage renal failure patients

1987 ◽  
Vol 20 (2) ◽  
pp. 105-109
Author(s):  
Kazumasa Shimamatsu ◽  
Satoru Fujimi ◽  
Kaoru Onoyama ◽  
Hiroshi Tsuruda ◽  
Masatoshi Fujishima
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Residual Renal Function ◽  
End Stage Renal Failure ◽  
Hemodialysis Treatment ◽  
End Stage

Evaluation of Induction Doses of Propofol: Comparison between Endstage Renal Disease and Normal Renal Function Patients

2002 ◽  
Vol 30 (5) ◽  
pp. 584-587 ◽  
Author(s):  
P. Goyal ◽  
G. D. Puri ◽  
C. K. Pandey ◽  
S. Srivastva
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Renal Disease ◽  
Normal Renal Function ◽  
End Stage Renal Disease ◽  
Objective Assessment ◽  
Haemoglobin Concentration ◽  
End Point ◽  
Stage Renal Disease ◽  
End Stage

Anaemia, hypoproteinaemia and acidic pH in renal failure patients can alter the pharmacokinetics and pharmaco-dynamics of anaesthetic agents, resulting in altered dose requirements. We evaluated the induction dose of propofol in adult patients with end-stage renal disease by titrating the hypnotic effect by means of a clinical parameter as well as using a more objective assessment of hypnosis, the Bispectral Index (BIS) monitor. The dose was compared with that for patients with normal renal function. Propofol doses that provided the clinical end-point of hypnosis (syringe drop method), as well as the end-point of a mean (SD) BIS value of 50 (5), were evaluated in 27 end-stage renal disease and 27 normal renal function patients. Propofol was administered at 0.2mg/kg every 15 seconds until these end-points were achieved. End-stage renal disease patients required significantly higher propofol doses to achieve the clinical end-point of hypnosis (1.42 (0.24) mg/kg versus 0.89 (0.2) mg/kg in normal renal function patients, P<0.05 unpaired “t” test). Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05). There was a significant negative correlation of propofol dose with preoperative haemoglobin concentration. A hyperdynamic circulation in renal failure patients with anaemia may be responsible for the higher propofol dose requirement in this group.

Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients

1997 ◽  
Vol 77 (04) ◽  
pp. 650-655 ◽  
Author(s):  
R Vanholder ◽  
A Camez ◽  
N Veys ◽  
A Van Loo ◽  
A M Dhondt ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Residual Renal Function ◽  
Hemodialysis Patients ◽  
The Body ◽  
Pharmacokinetic Data ◽  
High Flux ◽  
Recombinant Hirudin ◽  
End Stage Renal Failure ◽  
End Stage

SummaryRecently, hirudin was used for the first time as an anticoagulant during hemodialysis in men. Pharmacokinetic data of this compound in end-stage renal failure are however not available. In this study, the pharmacokinetics of recombinant hirudin (HBW 023) was evaluated in hemodialysis-treated end-stage renal failure patients. HBW 023 was administered as a bolus at the start of a single dialysis (0.02 to 0.08 mg/kg) in 20 patients, and plasma hirudin levels were followed during this and the 5 following dialyses, without additional hirudin administration. The initial dialysis (HDj) was performed with a low flux polysulfone dialyzer; the following dialyses (up to HD6) with a high flux polysulfone dialyzer and regular heparin. Hirudin levels averaged 504.0 ± 214.0 and 527.7 ± 217.1 ng/ml in the middle and at the end of HDj, and then gradually decreased to 15.2 ± 15.2 ng/ml at the end of HD6. Pharmacokinetic data were compared to those obtained in healthy controls (n = 5), receiving the same dose, and reaching the same peak hirudin level. Hirudin half-life was >30 times longer in hemodialysis patients (51.8 ± 15.6 vs. 1.7 ± 1.5 h, p <0.001), whereas area under the curve was >60 times higher (34,669 ± 14,898 vs. 545 ± 205 ng/ml X h, p <0.001). Distribution volume was lower in hemodialysis patients (11.0 ± 3.1 vs. 14.1 ± 2.0 1, p <0.05). Hirudin disappearance rate was the same during high flux polysulfone dialysis as during interdialytic periods. Hirudin removal was markedly higher in those patients still maintaining some residual renal function and parameters of hirudin removal were significantly correlated to residual creatinine clearance. It is concluded that hirudin removal from the body is markedly depressed in hemodialyzed end-stage renal failure patients and that even minor residual renal function may increase this removal rate.

Goodpasture's Syndrome Superimposed on Membranous Nephropathy. A Case Report

1995 ◽  
Vol 18 (12) ◽  
pp. 763-765 ◽  
Author(s):  
S. Thitiarchakul ◽  
S.M. Lal ◽  
A. Luger ◽  
G. Ross
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Case Report ◽  
Basement Membrane ◽  
Severe Hypertension ◽  
Maintenance Hemodialysis ◽  
Aggressive Therapy ◽  
End Stage Renal Failure ◽  
Membranous Glomerulopathy ◽  
End Stage

We describe a patient with idiopathic membranous glomerulopathy who developed acute deterioration in renal function; this was associated with hemoptysis, severe hypertension, and anti-glomerular basement membrane (anti-GBM) antibody in the serum. Despite aggressive therapy with plasmapheresis, cyclophosphamide and prednisone, the patient progressed to end-stage renal failure and is on maintenance hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document